These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 23124790

  • 1. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".
    Havla J, Berthele A, Kümpfel T, Krumbholz M, Jochim A, Kronsbein H, Ryschkewitsch C, Jensen P, Lippmann K, Hemmer B, Major E, Hohlfeld R.
    Mult Scler; 2013 Aug; 19(9):1213-5. PubMed ID: 23124790
    [Abstract] [Full Text] [Related]

  • 2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 3. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun 17; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 4. Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.
    Pietropaolo V, Bellizzi A, Anzivino E, Iannetta M, Zingaropoli MA, Rodio DM, Morreale M, Pontecorvo S, Francia A, Vullo V, Palamara AT, Ciardi MR.
    J Neurovirol; 2015 Dec 17; 21(6):653-65. PubMed ID: 25930159
    [Abstract] [Full Text] [Related]

  • 5. JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis.
    Travasarou M, Marousi S, Papageorgiou E, Karageorgiou CE.
    Clin Neurol Neurosurg; 2013 Jun 17; 115(6):827-9. PubMed ID: 22920632
    [No Abstract] [Full Text] [Related]

  • 6. JCV detection in multiple sclerosis patients treated with natalizumab.
    Sadiq SA, Puccio LM, Brydon EW.
    J Neurol; 2010 Jun 17; 257(6):954-8. PubMed ID: 20052484
    [Abstract] [Full Text] [Related]

  • 7. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
    Kapica-Topczewska K, Collin F, Tarasiuk J, Czarnowska A, Chorąży M, Mirończuk A, Kochanowicz J, Kułakowska A.
    Eur Neurol; 2020 Jun 17; 83(5):487-492. PubMed ID: 33027785
    [Abstract] [Full Text] [Related]

  • 8. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.
    JAMA Neurol; 2013 Mar 01; 70(3):398-402. PubMed ID: 23338729
    [Abstract] [Full Text] [Related]

  • 9. A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing.
    Mazda ME, Brosch JR, Wiens AL, Bonnin JM, Kamer AP, Mattson DH, Snook RJ.
    Int J Neurosci; 2013 May 01; 123(5):353-7. PubMed ID: 23252596
    [Abstract] [Full Text] [Related]

  • 10. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.
    Zingaropoli MA, Iannetta M, Pontecorvo S, Anzivino E, Prezioso C, Rodio DM, Morreale M, D'Abramo A, Oliva A, Lichtner M, Cortese A, Frontoni M, Pietropaolo V, Francia A, Mastroianni CM, Vullo V, Ciardi MR.
    Biomed Res Int; 2018 May 01; 2018():5297980. PubMed ID: 29682547
    [Abstract] [Full Text] [Related]

  • 11. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
    Fragoso YD, Mendes MF, Arruda WO, Becker J, Brooks JB, Carvalho Mde J, Comini-Frota ER, Domingues RB, Ferreira ML, Finkelsztejn A, Gama PD, Gomes S, Gonçalves MV, Kaimen-Maciel DR, Morales Rde R, Muniz A, Ruocco HH, Salgado PR, Albuquerque LB, Gama RA, Georgeto S, Lopes J, Oliveira CL, Oliveira FT, Safanelli J, Saldanha PC, Satomi M.
    Arq Neuropsiquiatr; 2013 Oct 01; 71(10):780-2. PubMed ID: 24212514
    [Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr 01; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 13. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
    Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I, Río J, Arrambide G, Comabella M, Arévalo MJ, Horno R, Vicente MJ, Caminero A, Nos C, Sastre-Garriga J, Montalban X.
    Mult Scler; 2012 Aug 01; 18(8):1193-6. PubMed ID: 22383232
    [Abstract] [Full Text] [Related]

  • 14. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.
    Mult Scler; 2015 Oct 01; 21(12):1600-3. PubMed ID: 25662344
    [Abstract] [Full Text] [Related]

  • 15. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Oct 01; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 16. Influence of JC virus coding region genotype on risk of multiple sclerosis and progressive multifocal leukoencephalopathy.
    Agostini HT, Ryschkewitsch CF, Baumhefner RW, Tourtellotte WW, Singer EJ, Komoly S, Stoner GL.
    J Neurovirol; 2000 May 01; 6 Suppl 2():S101-8. PubMed ID: 10871796
    [Abstract] [Full Text] [Related]

  • 17. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
    Blinkenberg M, Sellebjerg F, Leffers AM, Madsen CG, Sørensen PS.
    Mult Scler; 2013 Aug 01; 19(9):1226-9. PubMed ID: 23508652
    [Abstract] [Full Text] [Related]

  • 18. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients.
    Reid CE, Li H, Sur G, Carmillo P, Bushnell S, Tizard R, McAuliffe M, Tonkin C, Simon K, Goelz S, Cinque P, Gorelik L, Carulli JP.
    J Infect Dis; 2011 Jul 15; 204(2):237-44. PubMed ID: 21673034
    [Abstract] [Full Text] [Related]

  • 19. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
    Prezioso C, Zingaropoli MA, Iannetta M, Rodio DM, Altieri M, Conte A, Vullo V, Ciardi MR, Palamara AT, Pietropaolo V.
    Mult Scler Relat Disord; 2020 Jun 15; 41():102008. PubMed ID: 32087593
    [Abstract] [Full Text] [Related]

  • 20. High-resolution melting analysis for mutation scanning in the non-coding control region of JC polyomavirus from patients with progressive multifocal leukoencephalopathy.
    Nakamichi K, Tajima S, Lim CK, Saijo M.
    Arch Virol; 2014 Jul 15; 159(7):1687-96. PubMed ID: 24463953
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.